Celgene shows CAR-T confidence with $1bn Juno investment

Celgene is known as a creative yet disciplined dealmaker, so the fact that the big biotech company is investing $1bn up front under a 10-year agreement with Juno Therapeutics shows that Celgene sees a lot of value in the early-stage, closely-watched field of chimeric antigen T-cell receptor (CAR-T) therapies.